| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| NEUTRAL | NEUTRAL | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 5.64▼ | 5.68▼ | 5.67▼ | 5.45▲ | 5.42▲ |
| MA10 | 5.66▼ | 5.66▼ | 5.67▼ | 5.06▲ | 3.00▲ |
| MA20 | 5.65▼ | 5.64▼ | 5.57▲ | 5.28▲ | 1.92▲ |
| MA50 | 5.56▲ | 5.27▲ | 5.36▲ | 2.72▲ | 1.61▲ |
| MA100 | 5.38▲ | 4.93▲ | 4.10▲ | 1.77▲ | 2.72▲ |
| MA200 | 4.00▲ | 2.82▲ | 2.40▲ | 1.61▲ | 19.85▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.011▼ | -0.021▼ | -0.014▼ | -0.098▼ | 0.581▲ |
| RSI | 50.090▲ | 53.165▲ | 54.149▲ | 66.862▲ | 75.062▲ |
| STOCH | 42.598 | 54.384 | 55.949 | 62.879 | 62.588 |
| WILL %R | -65.306 | -65.306 | -37.069 | -24.643▲ | -23.163▲ |
| CCI | -6.699 | -58.409 | -9.063 | 86.095 | 92.914 |
|
Tuesday, September 09, 2025 05:29 AM
Salarius Pharmaceuticals ( ($SLRX) ) has issued an update. On September 4, 2025, Salarius Pharmaceuticals announced it had regained compliance ...
|
|
Tuesday, September 09, 2025 05:19 AM
By meeting the Minimum Bid Price Requirement, Salarius has achieved one of the milestones in regaining compliance with all Nasdaq continued listing standards. As previously disclosed on August 27, ...
|
|
Tuesday, September 09, 2025 05:16 AM
Salarius Pharmaceuticals (SLRX) announces that on September 4, 2025 the Company received notification from The Nasdaq Stock Market that it has ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 17/09/25 | 5.48 | 5.80 | 5.42 | 5.555 | 121,886 |
| 16/09/25 | 5.28 | 5.90 | 5.21 | 5.69 | 267,018 |
| 15/09/25 | 5.35 | 5.6199 | 4.79 | 5.445 | 3,061,889 |
| 12/09/25 | 5.35 | 5.4666 | 5.25 | 5.29 | 50,950 |
| 11/09/25 | 4.73 | 5.65 | 4.73 | 5.27 | 225,501 |
| 10/09/25 | 4.57 | 4.70 | 4.50 | 4.58 | 15,054 |
| 09/09/25 | 4.63 | 4.84 | 4.57 | 4.64 | 44,317 |
| 08/09/25 | 4.74 | 4.75 | 4.62 | 4.65 | 33,163 |
| 05/09/25 | 4.76 | 4.784 | 4.61 | 4.71 | 19,704 |
| 04/09/25 | 4.82 | 4.82 | 4.6554 | 4.74 | 19,381 |
|
|
||||
|
|
||||
|
|